<DOC>
	<DOCNO>NCT03070717</DOCNO>
	<brief_summary>This research project intend observe patient high myopia show pathological retinal change , order evaluate data risk factor develop mCNV within research project population Germany .</brief_summary>
	<brief_title>High Myopia : Extended Longterm Observation Pathologic Myopia Patients With Risk Developing Myopic Choroidal Neovascularization ( CNV )</brief_title>
	<detailed_description />
	<mesh_term>Myopia</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<criteria>Male female caucasian patient ≥ 18 year age Diagnosis high myopia secondary anteriorposterior elongation bulbus confirm ocular examination either eye use follow criterion : Ocular ultrasonography biometry demonstrate anteriorposterior elongation measurement ≥ 26 mm abnormal change retinal tissue SDOCT attribute caused high myopia show Table 42 protocol investigator 's discretion confirm read centre Patients Diabetes mellitus grade Patients show sign AgeRelated Macular Degeneration ( AMD ) , e.g . drusen , characteristic change fundus ( shape extension hemorrhage , fibrosis , exudative area ) either eye Acute neovascularization ( CNV iris neovascularization ) intra subretinal fluid either eye time enrolment . History inactive CNV study eye . Inactive CNV fellow eye allow treatment perform 12 month enrolment . Any anti vascular endothelial growth factor ' ( antiVEGF ) Verteporfin treatment study eye antiVEGF Verteporfin treatment le 12 month enrolment fellow eye History systemic anti vascular endothelial growth factor ' ( antiVEGF ) therapy Cataract would prevent accurate measurement axial length study eye Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>High myopia , shortsightedness , retinal change</keyword>
</DOC>